The demand for high-quality OEM components for respiratory and cardiovascular disease monitoring devices is increasing. “As the challenges of global healthcare become increasingly complex, we recognize the urgency and need for innovative solutions. This partnership brings together specialists in pulse oximetry and capnography who will use their combined sales channels to promote high-quality monitoring modules and devices to customers and, most importantly, to caregivers around the world” explains Dr. Jörg Pintaske, CEO of Corscience, on the occasion of the announcement of the strategic partnership.
Increasing threat from cardiovascular disease
The American Heart Association classifies cardiovascular disease as one of the greatest threats to the population in the USA. Last year, 41 percent of all deaths in the US were due to cardiovascular disease, followed by associated diseases such as strokes, high blood pressure and vascular disease. According to studies by the European Society of Cardiology (ESC), the figure in Europe is as high as 45 percent. State-of-the-art monitoring systems with precise capnography and pulse oximetry measurements can counteract these figures – they save lives. Therefore, seamless global coverage must be the goal.
Joint technologies for patient monitoring
Corscience’s CO2 monitoring solution and Nonin’s SpO2 monitoring solutions are highly complementary and both companies expect to expand their market presence through this co-promotion partnership. Corscience will be able to further extend its market presence with the proven CAP capnography module (available options for emergency, clinical and magnetic resonance imaging environments) in North America and other markets in the future, while Nonin Medical expects to expand its SpO2 monitoring solutions worldwide. “Nonin’s mission is to improve the lives of patients through noninvasive monitoring and we are excited to partner with Corscience. This partnership will expand access to high-quality capnography and pulse oximetry devices helping improve patient outcomes.” explains John Hastings, CEO of Nonin Medical.
